Log in

NYSE:PENPenumbra Stock Price, Forecast & News

$172.42
-0.30 (-0.17 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$167.07
Now: $172.42
$174.44
50-Day Range
$159.56
MA: $175.97
$191.72
52-Week Range
$121.80
Now: $172.42
$194.93
Volume253,900 shs
Average Volume245,347 shs
Market Capitalization$6.05 billion
P/E Ratio158.18
Dividend YieldN/A
Beta0.64
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Read More
Penumbra logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$547.41 million
Cash Flow$1.25 per share
Book Value$13.91 per share

Profitability

Net Income$48.46 million

Miscellaneous

Employees2,700
Market Cap$6.05 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

Penumbra (NYSE:PEN) Frequently Asked Questions

How has Penumbra's stock been impacted by COVID-19 (Coronavirus)?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PEN stock has decreased by 2.5% and is now trading at $172.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Penumbra?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Penumbra.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Penumbra.

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) released its earnings results on Thursday, May, 7th. The company reported $0.04 EPS for the quarter, missing the Zacks' consensus estimate of $0.10 by $0.06. The firm had revenue of $137.33 million for the quarter, compared to analyst estimates of $136.28 million. Penumbra had a return on equity of 5.72% and a net margin of 7.04%. The company's revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter last year, the business earned $0.23 EPS. View Penumbra's earnings history.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $137-137.3 million, compared to the consensus revenue estimate of $140.9 million.

What price target have analysts set for PEN?

6 analysts have issued 12 month target prices for Penumbra's shares. Their forecasts range from $180.00 to $214.00. On average, they anticipate Penumbra's share price to reach $191.67 in the next year. This suggests a possible upside of 11.2% from the stock's current price. View analysts' price targets for Penumbra.

Has Penumbra been receiving favorable news coverage?

News headlines about PEN stock have been trending very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Penumbra earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutPenumbra.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), AbbVie (ABBV), DexCom (DXCM), Intuitive Surgical (ISRG), Medtronic (MDT), Boeing (BA), salesforce.com (CRM) and Gilead Sciences (GILD).

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
  • Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
  • Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
  • Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
  • Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.85%), William Blair Investment Management LLC (3.61%), Wellington Management Group LLP (3.18%), Clearbridge Investments LLC (2.91%), Baillie Gifford & Co. (2.73%) and State Street Corp (2.28%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View institutional ownership trends for Penumbra.

Which institutional investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Alliancebernstein L.P., Clearbridge Investments LLC, Principal Financial Group Inc., Squarepoint Ops LLC, and Trexquant Investment LP. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, and Thomas Wilder. View insider buying and selling activity for Penumbra.

Which institutional investors are buying Penumbra stock?

PEN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Wellington Management Group LLP, Invesco Ltd., Balyasny Asset Management LLC, Champlain Investment Partners LLC, William Blair Investment Management LLC, Trillium Asset Management LLC, and Columbus Circle Investors. View insider buying and selling activity for Penumbra.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $172.42.

How big of a company is Penumbra?

Penumbra has a market capitalization of $6.05 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.